Metabolic
-
Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD
Osaka, Japan: Divestiture strategy on track Portfolio includes prescription products in Takeda’s Cardiovascular/Metabolic and Anti-inflammatory therapeutic areas along with Calcium Takeda…
Read More »